The authors suggest that the lower pCR rate observed in HER2-positive, HR-positive breast cancer patients may be due to the association with obesity and increased estrogen signaling pathways in HR-positive breast cancer, resulting in increased tumor proliferation and a worse response to neoadjuvant therapy. Here, ERBB2 is linked to obesity disorder.